MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

α-Synuclein Triggers Neuroinflammatory Damage through the suppression of MEF2C

X. Liu, E. Tao (Shenzhen, China)

Meeting: 2025 International Congress

Keywords: Alpha-synuclein, Inflammation

Category: Parkinson's Disease: Pathophysiology / molecular mechanisms of disease

Objective: To explore the effects of microglial myocyte enhancer factor 2C (MEF2C) in neuroinflammation induced by α-synuclein.

Background: The abnormal aggregation of α-synuclein (α-syn) is a critical pathological basis of Parkinson’s disease (PD). Excessive deposition of α-syn can trigger a pro-inflammatory response in microglia, mediating pathological spreading and neural degeneration. MEF2C, acting as an important neuroinflammatory “off” factor, plays a significant regulatory role in the process of neuron apoptosis.

Method: Cerebrospinal fluid (CSF) from PD patients was collected for microarray analysis. C57/BL6 mice and Human Microglial Cells (HMC3) were treated with α-syn (animals: 5 μg for 6 months; cells: 25μmol/L for 24 hours). Lentivirus was used to construct HMC3 cell models with MEF2C overexpression and knockdown (MEF2C-UP and MEF2C-KD). A co-culture system of HMC3 cells and SH-SY5Y cells was established. The mouse brain samples were used for immunohistochemistry and immunofluorescence assays. In vitro cells were analyzed using flow cytometry, PCR, WB, and ELISA to detect apoptosis rates, inflammatory cytokines, and apoptosis-related molecules. RNA antisense purification (RAP) and mass spectrometry were employed to identify regulatory proteins bound to MEF2C mRNA.

Results: Microarray analysis from patients, as well as results from in vivo and in vitro models, consistently demonstrated that the expression of MEF2C is downregulated in PD models. In HMC3 cells, compared to the control cells, the α-syn-treated cells and the MEF2C-KD cells exhibited increased apoptosis rates, elevated secretion of IL-17, IL-12p40, and IL-12p70, and an increased expression of Bax/Bcl-2 and cleaved caspase-3. SH-SY5Y cells co-cultured with these HMC3 cells also showed increased apoptosis rates, along with elevated expression levels of cleaved caspase-3 and p-RIPK1. RNA antisense purification (RAP) confirmed that nucleolin (NCL) and nucleophosmin (NPM1) bind to MEF2C mRNA. Furthermore, the suppression of NCL and NPM1 in microglia also promoted the aforementioned changes in neurons.

Conclusion: The present study reveals α-synuclein may modulate the expression of nucleolar proteins (NCL and NPM1) to suppress MEF2C, driving microglial neuroinflammation and causing neural damage and dysfunction.

To cite this abstract in AMA style:

X. Liu, E. Tao. α-Synuclein Triggers Neuroinflammatory Damage through the suppression of MEF2C [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/%ce%b1-synuclein-triggers-neuroinflammatory-damage-through-the-suppression-of-mef2c/. Accessed October 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/%ce%b1-synuclein-triggers-neuroinflammatory-damage-through-the-suppression-of-mef2c/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley